Sign inJoin waitlistJoin the waitlist

JR

Jerome Rubin

Credentials: ·

History

Hematology and Medical Oncology
Internal Medicine

Research

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN…
The Lancet Oncology · 2016 · 116 citations

Ahmed Khalid
1 paper
David Carbone
1 paper
GG
Gregory Gerstner
1 paper
Heather Wakelee
1 paper
Joel Neal
1 paper
PS
Philip Stella
1 paper
PS
Preston Steen
1 paper
RL
Rachel Lerner
1 paper
Seena Aisner
1 paper
Suresh Ramalingam
1 paper
Taofeek Owonikoko
1 paper